MedTrace Logo

A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma

NCT06656091 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2024-10-24

No results posted yet for this study

Summary

To evaluate the overall survival of simmitinib versus investigator's choice of chemotherapy for Participants with advanced or metastatic oesophageal squamous cell carcinoma who have disease progression after first-line standard therapy.

Conditions

  • Advanced Oesophageal Squamous Cell Carcinoma

Interventions

DRUG

simmitinib

simmitinib 6mg,QD ,3 weeks on 1 week off

DRUG

investigator's choice of chemotherapy,include docetaxel or irinotecan.

docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks

Sponsors & Collaborators

  • Shanghai Runshi Pharmaceutical Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ruihua Xu · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2027-01-30
Completion
2027-01-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06656091 on ClinicalTrials.gov